Dermatology Studies - enrolling now
-
Topical Agents for Hidradenitis Suppurativa
Phase 3, randomized, double-blind, controlled, efficacy, and safety study of a topical cream in participants age 12 and up with mild to moderate Hidradenitis Suppurativa
-
Oral Agents for Hidradenitis Suppurativa
Phase 3, randomized, double-blind, efficacy and safety study of an oral agent in adults with moderate to severe Hidradenitis Suppurativa (and Long-Term Extension Study)
-
Injectable Agents for Hidradenitis Suppurativa
A Phase 3 randomized, double-blind, controlled, efficacy and safety study of a subcutaneous injection in adults with moderate to severe Hidradenitis Suppurativa
Phase 2b, randomized, double-blind, controlled, efficacy, and safety study of a subcutaneous injection in adults with moderate to severe Hidradenitis Suppurativa
-
Teen Hidradenitis Suppurativa
Phase 3, open-label, single-arm study to evaluate pharmacokinetics and safety of a subcutaneous injection in adolescents, ages 12-17, with moderate to severe Hidradenitis Suppurativa
Our
Team
-
Dr. So Yeon Paek (MD)
Principal Investigator
-
Xochitl Flores (CRC)
Study Coordinator/Regulatory Affairs
-
Quinette Haynes (CRC)
Study Coordinator/Regulatory Affairs
-
Claire Jung (PA-C)
Sub-Investigator